Financing ·
On July 23, 2026, Summit Therapeutics Inc. entered into an at-the-market distribution agreement with J.P. Morgan…
SMMTSummit Therapeutics Inc.
On July 23, 2026, Summit Therapeutics Inc. entered into an at-the-market distribution agreement with J.P. Morgan Securities LLC. The agreement allows the company to sell shares of its common stock with an aggregate offering price of up to $380,000,000. J.P. Morgan will receive a commission of up to 3.0% of the gross sales price per share. The company is not obligated to sell any shares under this agreement. Summit Therapeutics is a biopharmaceutical company that develops and commercializes therapies for various diseases.